Alternatives to PrEP: Creating Safe, Effective Options
On September 23, 2021, industry publication Fierce Pharma reported that the U.S. Food and Drug Administration (FDA) granted priority review status to cabotegravir, a long-acting version of pre-exposure prophylaxis (PrEP). As early as January 2022, the FDA could issue its…